Larimar Therapeutics Inc (LRMR)

12.440
-0.620(-4.75%)
Pre Market
12.110
-0.330(-2.65%)
- Real-time Data
  • Volume:
    102,250
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    12.190 - 13.230

LRMR Overview

Prev. Close
13.06
Day's Range
12.19-13.23
Revenue
-
Open
12.95
52 wk Range
7.01-25.87
EPS
-3.07
Volume
102,250
Market Cap
220.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
134,437
P/E Ratio
-
Beta
0.9
1-Year Change
-29.32%
Shares Outstanding
17,710,450
Next Earnings Date
Nov 16, 2021
What is your sentiment on Larimar Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Larimar Therapeutics Inc News

Larimar Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell

Larimar Therapeutics Inc Company Profile

Larimar Therapeutics Inc Company Profile

Employees
28

Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.

Read More
  • What 7$
    1
    • Q
      1
      • Watch your head as this is gonna fall!
        1
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.